FDA approves first buprenorphine implant for treatment of opioid dependence
The FDA has approved Probuphine, the first buprenorphine implant for maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine. May 26, 2016